ES2152380T3 - Analogos de hgh-rh(1-29)nh2 con actividad antagonista. - Google Patents

Analogos de hgh-rh(1-29)nh2 con actividad antagonista.

Info

Publication number
ES2152380T3
ES2152380T3 ES95904767T ES95904767T ES2152380T3 ES 2152380 T3 ES2152380 T3 ES 2152380T3 ES 95904767 T ES95904767 T ES 95904767T ES 95904767 T ES95904767 T ES 95904767T ES 2152380 T3 ES2152380 T3 ES 2152380T3
Authority
ES
Spain
Prior art keywords
ala
cit
sub
abu
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95904767T
Other languages
English (en)
Inventor
Andrew V Schally
Marta Zarandi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tulane University
Original Assignee
Tulane University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tulane University filed Critical Tulane University
Application granted granted Critical
Publication of ES2152380T3 publication Critical patent/ES2152380T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth-hormone releasing factors (GH-RF) (Somatoliberin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE PRESENTAN ANALOGOS SINTETICOS DEL HGH - RH(1-29)NH 2} QUE TIENEN SUSTITUCIONES DE DIFERENTES AMINOACIDOS Y QUE ESTAN ACILADOS EN EL TERMINAL N, Y QUE EXHIBEN UNA DURACION ANTAGONISTICA PROLONGADA. CONFORMACIONES DIFERENTES INCLUYEN ANALOGOS DE LA FORMULA: X - R1 - R2 - R3 - R4 - R5 - R6 - THR R8 SER - TYR - R11 - R12 - VAL - LEU - R15 - GIN - LEU - SER R19 - R20 - R21 - LEU - LEU - GIN - ASP - ILE - R27 - R28 - R29, EN DONDE X ES NIL, H AC, IAC, BRPROP, FOR, IBU, NAC, 2- NAC, 1O2 - NPT, 1-O2-NPR O AQC, R1 ES TYR, HIS, GLU, O GLT, R2 ES DARG, D-CIT, D-HAR, D-LYS, O D-ORN, R3 ES ASP, ALA, O GLY; R4 ES ALA O GLY, R5 ES ILE, ALA O GLY; R6 ES PHE, ALA, PRO, TPI, NAL O PHE(Y), EN DONDE Y ES F, CL, BR, NO{SUB, 2}, CH{SUB, 3} O OCH{SUB, 3}; R8 ES ASN, SER, VAL, ILE, ALA, ABU, NLE O AIB; R11 ES ARJ, D-ARJ, O CIT; R12 ES LYS, D-LYS CIT O ALA; R15 ES GLY, ALA, ABU O GLN; R19 ES ALA O ABU; R20 ES ARG, D-ARG O CIT; R21 ES LYS, D-LYS O CIT; R27 ES MET, NLE O ABU; R28 ES SER, ASN, ASP O ABU; R29 ES AGM, ARG-NH{SUB, 2}, ARG-OH, CIT-NH{SUB, 2}, CITOH, HAR-NH{SUB, 2} O HAR-OH; TENIENDO EN CUENTA QUE CUANDO R1 ES GLT, X ES NULA Y CUANDO X ES H, R15 ES DIFERENTE DE GLY, ASIMISMO SE PRESENTAN LAS SALES DE ADICION ACIDA FARMACOLOGICAMENTE ACEPTABLES DE LOS MISMOS.
ES95904767T 1993-12-17 1994-11-28 Analogos de hgh-rh(1-29)nh2 con actividad antagonista. Expired - Lifetime ES2152380T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/168,810 US5550212A (en) 1993-12-17 1993-12-17 Analogues of hGH-RH(1-29)NH2 having antagonistic activity

Publications (1)

Publication Number Publication Date
ES2152380T3 true ES2152380T3 (es) 2001-02-01

Family

ID=22613022

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95904767T Expired - Lifetime ES2152380T3 (es) 1993-12-17 1994-11-28 Analogos de hgh-rh(1-29)nh2 con actividad antagonista.

Country Status (13)

Country Link
US (1) US5550212A (es)
EP (1) EP0734396B1 (es)
JP (1) JPH09506616A (es)
AU (1) AU695315B2 (es)
CA (1) CA2178218A1 (es)
DE (1) DE69426270T2 (es)
DK (1) DK0734396T3 (es)
ES (1) ES2152380T3 (es)
GR (1) GR3035170T3 (es)
NZ (1) NZ277926A (es)
PT (1) PT734396E (es)
WO (1) WO1995016707A1 (es)
ZA (1) ZA949641B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5792747A (en) * 1995-01-24 1998-08-11 The Administrators Of The Tulane Educational Fund Highly potent agonists of growth hormone releasing hormone
US5942489A (en) * 1996-05-03 1999-08-24 The Administrators Of The Tulane Educational Fund HGH-RH(1-29)NH2 analogues having antagonistic activity
AU768516B2 (en) * 1998-06-03 2003-12-18 Ardana Bioscience Limited Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
US6124263A (en) * 1998-11-16 2000-09-26 Asta Medica Ag Treatment of tumors by administration of growth hormone releasing compounds and their antagonists
US6057422A (en) * 1998-11-25 2000-05-02 The Administrators Of The Tulane Educational Fund Antagonistic analogs of GH-RH inhibiting IGF-I and -II
FR2821359B1 (fr) * 2001-02-27 2003-05-09 Sod Conseils Rech Applic L'heterocarpine, une proteine fixant le ghrh humain
FR2843697B1 (fr) * 2002-08-26 2005-12-09 Sod Conseils Rech Applic L'heterocarpine, une proteine d'origine vegetale aux proprietes anticancereuses
US7494969B2 (en) 2002-02-26 2009-02-24 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Heterocarpine, a plant-derived protein with anti-cancer properties
US8691942B2 (en) 2008-03-28 2014-04-08 University Of Miami N- and C- terminal substituted antagonistic analogs of GH-RH
BRPI0915888E2 (pt) 2008-06-12 2020-09-01 Syntaxin Ltd polipetídeo, seu método de ativação, sequência de ácido nucléico codificando o mesmo e seu uso
EP2310029B1 (en) 2008-06-12 2019-04-03 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of cancer
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
EP3218395B1 (en) 2014-11-12 2022-01-05 The United States of America, as represented by The Secretary, Department of Health and Human Services Treatment of hormonal disorders of growth
US20170121385A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518586A (en) * 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US4628043A (en) * 1983-04-26 1986-12-09 The Salk Institute For Biological Studies Hypothalamic GRF agonists
US4626523A (en) * 1983-09-13 1986-12-02 The Salk Institute For Biological Studies GRF analogs II
US4528190A (en) * 1983-10-25 1985-07-09 The Salk Institute For Biological Studies GRF Analogs IV
US4659693A (en) * 1984-04-30 1987-04-21 Syntex (U.S.A.) Inc. N,N'-dialkyl substituted guanidino amino acyl residue substituted GRF-analog peptides
FR2567524B1 (fr) * 1984-07-10 1987-11-27 Sanofi Sa Procede de synthese de la somatocrinine en phase liquide et peptides intermediaires
US4649131A (en) * 1984-09-24 1987-03-10 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4622312A (en) * 1984-09-24 1986-11-11 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
CA1271600A (en) * 1985-01-07 1990-07-10 David Howard Coy Growth hormone-releasing peptides and method of treating mammals therewith
US4689318A (en) * 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US4880778A (en) * 1986-05-12 1989-11-14 Eastman Kodak Company Combinations having synergistic growth hormone releasing activity and methods for use thereof
US4784987A (en) * 1987-01-13 1988-11-15 The Salk Institute For Biological Studies GRF analogs VI
US4914189A (en) * 1987-02-05 1990-04-03 The Adminstrators Of The Tulane Educational Fund Synthetic GHRH analogs
US4800191A (en) * 1987-07-17 1989-01-24 Schally Andrew Victor LHRH antagonists
US5084555A (en) * 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
EP0413839A1 (en) * 1989-08-22 1991-02-27 The Administrators of The Tulane Educational Fund GHRH analogs
JPH06502618A (ja) * 1990-05-04 1994-03-24 ジ・アドミニストレイターズ・オブ・ザ・テュレイン・エデュケイショナル・ファンド 新規な合成ｇｒｆ類似物
JP3051145B2 (ja) * 1990-08-28 2000-06-12 住友製薬株式会社 新規なポリエチレングリコール誘導体修飾ペプチド
JP2707938B2 (ja) * 1993-01-06 1998-02-04 株式会社ニコン 発光素子を有するカメラおよび電子閃光装置

Also Published As

Publication number Publication date
CA2178218A1 (en) 1995-06-22
NZ277926A (en) 1997-12-19
EP0734396A1 (en) 1996-10-02
PT734396E (pt) 2001-04-30
AU1332295A (en) 1995-07-03
WO1995016707A1 (en) 1995-06-22
AU695315B2 (en) 1998-08-13
ZA949641B (en) 1995-08-25
JPH09506616A (ja) 1997-06-30
DK0734396T3 (da) 2001-02-12
DE69426270T2 (de) 2001-07-05
EP0734396B1 (en) 2000-11-08
GR3035170T3 (en) 2001-04-30
DE69426270D1 (de) 2000-12-14
US5550212A (en) 1996-08-27

Similar Documents

Publication Publication Date Title
ES2152380T3 (es) Analogos de hgh-rh(1-29)nh2 con actividad antagonista.
ES2163444T3 (es) Composiciones y metodos para la administracion oral de farmacos.
ATE178613T1 (de) Zyklische peptide mit aggregationshemmenden eigenschaften
NZ502872A (en) Mevinolin and compaction as LFA-1 antagonists for treating autoimmune diseases
DK222989D0 (da) Antiaggregatoriske peptider, farmaceutiske midler indeholdende peptiderne samt fremgangsmaader til anvendelse heraf
CA2121724A1 (en) Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
HUP0003592A2 (hu) LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények
ATE278708T1 (de) Conotoxin peptid pviia
AR040955A1 (es) Analogos de ghrelina
KR930701483A (ko) Grf (쥐이알에프) 유사체 xi
DK0914340T3 (da) hGH-RH(1-29)NH2-analoger med antagonistisk aktivitet
ATE103609T1 (de) Zyklische grf-analoge.
CO5180565A1 (es) Analogos antagonistas de gh-rh que inhiben igf-i y ii
DE69201438T2 (de) Als therapeutika geeignete peptide.
KR880013974A (ko) 합성펩티드와 이를 포함하는 제약학적 조성물
DK0579363T3 (da) Behandling af tropisk spastisk parese med peptid T
KR950702574A (ko) 펩티드 폐 계면활성제 및 치료용 혼합물(Peptide Lung Surfactants and Therapeutic Combinations)
EP0346068A3 (en) D-cys6 vasopressin antagonists
KR890005149A (ko) 합성 펩타이드 및 이를 포함한 제약학적 조성물
Donaldson et al. Effect of some analogues of bradykinin upon vascular permeability.
TH2785EX (th) สารคล้ายคลึง จีอาร์เอฟ
TH1778EX (th) สารคล้ายคลึง จี อาร์ เอฟ (grf)
BR0311238A (pt) Empregos de cefaibolen
IT1196502B (it) Analoghi parzialmente retro invertiti della tuftsina
RU99100332A (ru) Производные пептидов

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 734396

Country of ref document: ES